| EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE | Gilead | ||
| 200MG; EQ 25MG BASE; 300MG, Tablet Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
|
Less Than 5
|
Less Than 5
|
||
| Indicated as a complete regimen for the treatment of HIV-1 infection | |||
|
Yes
| |||
| COMPLERA | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | ******* | ******* | ******* | *** ********* | *** ********* | ******* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | ******* | ******* | ******* | ******* |
| ****** **** | *** ********* | ******* **** **** | ******* **** **** | ******* **** **** | ******* **** **** | *** ********* | ******* **** **** | ******* **** **** | ******* | *** ********* | *** ********* | **** ** *** **, **** | **** ** *** **, **** |
| *********** ************ ********** *********** *** *** ********* ********** ******** | *** ********** *********** *********** | ********* *** *** *********** ** *-[[*-[[*-(*-************)-*,*-**************]*****]-*-************]*****]************ | ********* *** *** *********** ** *-[[*-[[*-(*-************)-*,*-**************]*****]-*-***********]*****]************ | *** ********** *********** *********** | **** ** *-[[*-[[*-(*-************)-*,*-**************]*****]-*-***********]*****]************ | ******* *** ********* *-[(*,*-*******-*-***-*-***********)*****]************ | ************ *** ******* *** *********** ********* ******* | ******* *** ********* *-[(*,*-*******-*-***-*-***********)*****]************ | ************ *** ******* *** *********** ********* ******* | ************ ** * ********** ********** ***** **** ** ********** | ************ *** ******* *** *********** ********* ******* | ************ *** ******* *** *********** ********* ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** \ *** | ***, **** | ******* | ******** | ******** ** *** **, **** |
| ****** **** | ** \ ** | *** **, **** | ******* / ********* ******* | **** | *** ****** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|